Tech Company Financing Transactions
Global Blood Therapeutics Funding Round
On 1/6/2015, Global Blood Therapeutics raised $48 million in Series B funding from Deerfield Capital, Perceptive Advisors and RA Capital.
Transaction Overview
Company Name
Announced On
1/6/2015
Transaction Type
Venture Equity
Amount
$48,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the company's lead drug candidate, GBT440, for the treatment of sickle cell disease (SCD). GBT440 has shown promising results in preclinical testing and the company is initiating a Phase I/II clinical trial.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
171 Oyster Point Blvd. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Global Blood Therapeutics develops oral medicines for the treatment of chronic blood-based diseases and severe genetic disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Operating Officer
David Johnson
VP - Bus. Development
Jung Choi
VP - Bus. Development
Josh Lehrer
VP - General Counsel
Tricia Suvari
VP - Operations
Peter Radovich
Browse more venture capital transactions:
Prev: 1/6/2015: IntegriCo Composites venture capital transaction
Next: 1/7/2015: ZeroTurnaround venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs